Novartis AG (NVS)
NYSE: NVS · IEX Real-Time Price · USD
110.32
+0.39 (0.35%)
At close: Jul 26, 2024, 4:00 PM
112.68
+2.36 (2.14%)
After-hours: Jul 26, 2024, 7:52 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $12.87B in the quarter ending June 30, 2024, with 9.60% growth. This brings the company's revenue in the last twelve months to $48.86B, up 9.70% year-over-year. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
$48.86B
Revenue Growth
+9.70%
P/S Ratio
4.42
Revenue / Employee
$642,413
Employees
76,057
Market Cap
215.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 81.80B |
| Merck & Co. | 61.40B |
| Pfizer | 55.09B |
| AbbVie | 54.40B |
| AstraZeneca | 47.61B |
| Thermo Fisher | 42.49B |
| Abbott Laboratories | 40.33B |
| Amgen | 29.53B |
NVS News
- 2 days ago - Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer - Business Wire
- 8 days ago - Novartis Falls Despite Earnings Beat, Guidance Raise - Investopedia
- 8 days ago - Novartis lifts guidance again as demand climbs for top drugs - Market Watch
- 8 days ago - Novartis raises 2024 profit guidance for second time - Reuters
- 8 days ago - Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance - GlobeNewsWire
- 6 weeks ago - Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment - GlobeNewsWire
- 7 weeks ago - Novartis and others face Italy antitrust probe over eye drug - Reuters
- 2 months ago - Novartis leukemia drug more effective than older treatments in trial - Reuters